Next generation therapies change the landscape in melanoma

od Flaherty, Keith T.
Izdano 2011

When are signal transduction targeted therapies acting as immunotherapy?

od Flaherty, Keith T
izdano v Cancer Biol Ther (2015)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

od Sullivan, Ryan J., Flaherty, Keith T.
Izdano 2011

Moving treatments earlier to move further forward

od Davies, Michael A., Flaherty, Keith T.
izdano v Nat Rev Clin Oncol (2017)

Targeting the RAS pathway in melanoma

od Ji, Zhenyu, Flaherty, Keith T., Tsao, Hensin
Izdano 2011

Biological challenges of BRAF inhibitor therapy

od Puzanov, Igor, Burnett, Patrick, Flaherty, Keith T.
izdano v Mol Oncol (2011)

Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

od Bai, Xue, Fisher, David E., Flaherty, Keith T.
izdano v Nat Rev Clin Oncol (2019)

Mutation-driven drug development in melanoma

od Flaherty, Keith T., Hodi, F. Stephen, Bastian, Boris C.
Izdano 2010

Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

od Wargo, Jennifer A., Cooper, Zachary A., Flaherty, Keith T.
izdano v Cancer Discov (2014)

Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma

od Verduzco, Daniel, Flaherty, Keith T., Smalley, Keiran S.M.
izdano v Exp Dermatol (2015)

YAP in MAPK pathway targeted therapy resistance

od Flaherty, Keith T, Wargo, Jennifer A, Bivona, Trever G
izdano v Cell Cycle (2015)

Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy

od Lo, Jennifer A., Fisher, David E., Flaherty, Keith T.
izdano v JAMA Oncol (2015)

Mechanisms of resistance to immune checkpoint inhibitors

od Jenkins, Russell W, Barbie, David A, Flaherty, Keith T
izdano v Br J Cancer (2018)

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: Where we have been, are, and will be

od Sullivan, Ryan J., LoRusso, Patricia M., Flaherty, Keith T.
Izdano 2013

The Conundrum of Genetic “Drivers” in Benign Conditions

od Kato, Shumei, Lippman, Scott M., Flaherty, Keith T., Kurzrock, Razelle
izdano v J Natl Cancer Inst (2016)

Melanoma: New Insights and New Therapies

od Nikolaou, Vasiliki A., Stratigos, Alexander J., Flaherty, Keith T., Tsao, Hensin
Izdano 2012

Precision medicine for cancer with next-generation functional diagnostics

od Friedman, Adam A., Letai, Anthony, Fisher, David E., Flaherty, Keith T.
izdano v Nat Rev Cancer (2015)

Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

od Fofaria, Neel M., Frederick, Dennie T., Sullivan, Ryan J., Flaherty, Keith T., Srivastava, Sanjay K.
izdano v Oncotarget (2015)

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape

od Fedorenko, Inna V., Wargo, Jennifer A., Flaherty, Keith T., Messina, Jane L., Smalley, Keiran S.M.
izdano v J Invest Dermatol (2015)

A Melanoma Molecular Disease Model

od Vidwans, Smruti J., Flaherty, Keith T., Fisher, David E., Tenenbaum, Jay M., Travers, Michael D., Shrager, Jeff
Izdano 2011